Orchid Pharma witnessed a sharp decline of over 14% in its stock price after the company reported weak financial results for Q3. As of 10:27 AM, the shares were trading 14.78% lower at Rs 1,051.65.
For the quarter ended December 2024, Orchid Pharma’s consolidated revenue dropped 1.37% year-on-year to ₹217 crore from ₹220 crore.
The company’s EBITDA fell significantly by 24.05% to ₹26.4 crore, down from ₹34.76 crore in the same period last year. EBITDA margins also took a hit, contracting by 363 basis points to 12.16% from 15.8%. Net profit declined sharply by 25.63% to ₹22.45 crore, compared to ₹30.19 crore in the previous year.
Orchid Pharma’s shares opened at ₹1,214.95, reaching a high of ₹1,214.95 and a low of ₹992.65. The stock remains volatile, with a 52-week high of ₹1,997.40 and a low of ₹913.25.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
